-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Immunotherapy, edited by WuXi AppTec's content team, has become the fifth pillar of cancer treatment in addition to surgery, radiotherapy, chemotherapy, and targeted therapies.
The anti-cancer progress report released by the American Association for Cancer Research (AACR) last year pointed out that as of July 31, 2020, at least one immunotherapy can be used to treat 16 cancer types including lung cancer, liver cancer, stomach cancer, breast cancer, etc.
.
The expansion of immunotherapy from second-line and third-line therapy to first-line and adjuvant therapy, bringing the possibility of cure for patients at an earlier stage of cancer development, and prolonging their lives, is an important direction for the development of immunotherapy.
Today, Bristol-Myers Squibb (BMS) and Merck & Co.
(MSD) announced the positive results of their respective blockbuster PD-1 inhibitors in first-line and adjuvant therapy.
Bristol-Myers Squibb's Opdivo first-line combination therapy prolongs the lives of patients with esophageal squamous cell carcinoma.
Esophageal cancer is the sixth leading cause of cancer deaths in the world, and China is a country with a high incidence of esophageal cancer.
The number of patients and the number of deaths due to esophageal cancer are close to the world's total.
half.
The majority of esophageal cancer patients in China are squamous cell carcinoma, accounting for about 90% of the total number of patients.
Most patients with esophageal cancer are locally advanced or have distant metastases at the time of diagnosis.
Today, Bristol-Myers Squibb announced that its blockbuster PD-1 inhibitor Opdivo (nivolumab, nivolumab), combined with chemotherapy or chemotherapy + anti-CTLA-4 monoclonal antibody Yervoy, as a first-line therapy in the treatment of unresectable The primary endpoint was reached in a phase 3 clinical trial in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Interim results analysis showed that the combination of Opdivo and chemotherapy significantly prolonged the overall survival (OS) of patients compared with chemotherapy.
At the same time, this combination also brings a statistically significant and clinically significant improvement in the progression-free survival (PFS) of patients whose tumors express PD-L1.
Opdivo combined with chemotherapy and Yervoy also significantly prolonged the overall survival of patients.
However, in patients whose tumors express PD-L1, this combination therapy did not reach the primary endpoint of PFS.
Previously, the combination therapy of Opdivo and chemotherapy has obtained positive results in first-line clinical trials for patients with gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma, reducing the risk of death by 20%.
This latest result means that Opdivo and chemotherapy constitute the first-line therapy to show consistent superiority in the treatment of upper gastrointestinal cancer, regardless of where the cancer occurs and what tissue type it has.
In addition, Opdivo, as an adjuvant therapy, doubled the patient's disease-free survival when treating patients with early esophageal cancer and GEJ cancer undergoing surgical resection.
This result has been published in the New England Journal of Medicine recently.
These results further prove that Opdivo can provide clinical benefits to patients with esophageal cancer of various types and stages of cancer development.
Merck’s PD-1 inhibitor Keytruda prolongs the “cancer-free survival” time of patients with early-stage renal cell carcinoma.
Renal cell carcinoma is the most common type of renal cancer, accounting for 90% of the total number of renal cancers.
It is estimated that there will be more than 430,000 newly diagnosed kidney cancer patients worldwide in 2020, and nearly 180,000 of them will die as a result.
Merck’s blockbuster PD-1 inhibitor Keytruda has been approved by the FDA for the first-line treatment of renal cell carcinoma in combination with chemotherapy.
Today, the company announced that Keytruda, as an adjuvant therapy, has also obtained positive results in a phase 3 clinical trial for the treatment of patients with early-stage renal cell carcinoma undergoing surgical treatment.
According to an interim analysis by the Independent Data Review Board, Keytruda significantly improved disease-free survival (DFS) in patients with renal cell carcinoma who had undergone total nephrectomy or renal and metastatic lesions compared with placebo.
Primary endpoint.
This clinical trial will continue to evaluate the impact of Keytruda treatment on the overall survival of patients.
Dr.
Roy Baynes, Chief Medical Officer of Merck Laboratories, said that this is the first time that anti-PD-1 therapy has been used as an adjuvant therapy and has achieved positive results in the treatment of patients with early renal cell carcinoma.
We look forward to the success of immunotherapy in more clinical trials for the treatment of patients with early-stage cancer and prolong their "cancer-free survival" time and life.
References: [1] Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Retrieved April 8, 2021, from https:/ /www.
businesswire.
com/news/home/20210408005274/en[2] Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery.
Retrieved April 8, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
The anti-cancer progress report released by the American Association for Cancer Research (AACR) last year pointed out that as of July 31, 2020, at least one immunotherapy can be used to treat 16 cancer types including lung cancer, liver cancer, stomach cancer, breast cancer, etc.
.
The expansion of immunotherapy from second-line and third-line therapy to first-line and adjuvant therapy, bringing the possibility of cure for patients at an earlier stage of cancer development, and prolonging their lives, is an important direction for the development of immunotherapy.
Today, Bristol-Myers Squibb (BMS) and Merck & Co.
(MSD) announced the positive results of their respective blockbuster PD-1 inhibitors in first-line and adjuvant therapy.
Bristol-Myers Squibb's Opdivo first-line combination therapy prolongs the lives of patients with esophageal squamous cell carcinoma.
Esophageal cancer is the sixth leading cause of cancer deaths in the world, and China is a country with a high incidence of esophageal cancer.
The number of patients and the number of deaths due to esophageal cancer are close to the world's total.
half.
The majority of esophageal cancer patients in China are squamous cell carcinoma, accounting for about 90% of the total number of patients.
Most patients with esophageal cancer are locally advanced or have distant metastases at the time of diagnosis.
Today, Bristol-Myers Squibb announced that its blockbuster PD-1 inhibitor Opdivo (nivolumab, nivolumab), combined with chemotherapy or chemotherapy + anti-CTLA-4 monoclonal antibody Yervoy, as a first-line therapy in the treatment of unresectable The primary endpoint was reached in a phase 3 clinical trial in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Interim results analysis showed that the combination of Opdivo and chemotherapy significantly prolonged the overall survival (OS) of patients compared with chemotherapy.
At the same time, this combination also brings a statistically significant and clinically significant improvement in the progression-free survival (PFS) of patients whose tumors express PD-L1.
Opdivo combined with chemotherapy and Yervoy also significantly prolonged the overall survival of patients.
However, in patients whose tumors express PD-L1, this combination therapy did not reach the primary endpoint of PFS.
Previously, the combination therapy of Opdivo and chemotherapy has obtained positive results in first-line clinical trials for patients with gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma, reducing the risk of death by 20%.
This latest result means that Opdivo and chemotherapy constitute the first-line therapy to show consistent superiority in the treatment of upper gastrointestinal cancer, regardless of where the cancer occurs and what tissue type it has.
In addition, Opdivo, as an adjuvant therapy, doubled the patient's disease-free survival when treating patients with early esophageal cancer and GEJ cancer undergoing surgical resection.
This result has been published in the New England Journal of Medicine recently.
These results further prove that Opdivo can provide clinical benefits to patients with esophageal cancer of various types and stages of cancer development.
Merck’s PD-1 inhibitor Keytruda prolongs the “cancer-free survival” time of patients with early-stage renal cell carcinoma.
Renal cell carcinoma is the most common type of renal cancer, accounting for 90% of the total number of renal cancers.
It is estimated that there will be more than 430,000 newly diagnosed kidney cancer patients worldwide in 2020, and nearly 180,000 of them will die as a result.
Merck’s blockbuster PD-1 inhibitor Keytruda has been approved by the FDA for the first-line treatment of renal cell carcinoma in combination with chemotherapy.
Today, the company announced that Keytruda, as an adjuvant therapy, has also obtained positive results in a phase 3 clinical trial for the treatment of patients with early-stage renal cell carcinoma undergoing surgical treatment.
According to an interim analysis by the Independent Data Review Board, Keytruda significantly improved disease-free survival (DFS) in patients with renal cell carcinoma who had undergone total nephrectomy or renal and metastatic lesions compared with placebo.
Primary endpoint.
This clinical trial will continue to evaluate the impact of Keytruda treatment on the overall survival of patients.
Dr.
Roy Baynes, Chief Medical Officer of Merck Laboratories, said that this is the first time that anti-PD-1 therapy has been used as an adjuvant therapy and has achieved positive results in the treatment of patients with early renal cell carcinoma.
We look forward to the success of immunotherapy in more clinical trials for the treatment of patients with early-stage cancer and prolong their "cancer-free survival" time and life.
References: [1] Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Retrieved April 8, 2021, from https:/ /www.
businesswire.
com/news/home/20210408005274/en[2] Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery.
Retrieved April 8, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
